(Corrects Overview section and Key Details table to show

revenue met, not missed, analysts expectations)

Overview

* Zimmer Biomet ( ZBH ) Q3 net sales rose 9.7%, meeting analyst

expectations

* Adjusted EPS for Q3 beats consensus, increasing by 9.2%

* Company's U.S. growth driven by new product adoption,

offset by

regional weaknesses

Outlook

* Zimmer Biomet ( ZBH ) maintains full-year revenue growth guidance

at

6.7% to 7.7%

* Company narrows full-year constant currency revenue growth

to

6.2% to 6.7%

* Zimmer Biomet ( ZBH ) projects full-year adjusted EPS between

$8.10 and

$8.30

Result Drivers

* U.S. GROWTH - 5.6% organic revenue growth in U.S. driven

by

adoption of new products, per CEO Ivan Tornos

* REGIONAL WEAKNESS - Performance offset by weakness in

Latin

America, Emerging Markets in Europe, and non-core businesses

* NEW TECHNOLOGIES - Upcoming launch of iodine-treated hip

implant

and autonomous robot expected to drive growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Meet $2 bln $2 bln

(22

Analysts

)

Q3 Beat $1.90 $1.86

Adjusted (24

EPS Analysts

)

Q3 EPS $1.16

Q3 Net $230.90

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold"

and

the breakdown of recommendations is 11 "strong buy" or "buy", 17

"hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the medical

equipment,

supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Zimmer

Biomet

Holdings Inc ( ZBH ) is $108.00, about 4.5% above its November 4 closing

price of $103.18

* The stock recently traded at 12 times the next 12-month

earnings

vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact

[email protected]. For any other questions or feedback,

contact .

(This story was created using Reuters automation and AI based

on LSEG and company data. It was checked and edited by a Reuters

journalist prior to publication.)